Coronary artery stenosis is one of the common types of cardiovascular diseases and one of the important causes of cardiac ischemia. At present, the common treatment methods of this disease include drug therapy, percutaneous coronary intervention and surgical heart bypass grafting. The treatment methods are still being explored and updated to meet the needs of a variety of diseases and complex lesions. The emergence of the concept of “intervention without implantation” and innovative products has important milestone significance in the field of interventional therapy of coronary heart disease, and brings new choices and hopes to patients with coronary heart disease.
Recently, a class III hospital in Beijing successfully completed an operation to treat patients with coronary heart disease with neovas bioabsorbable stent and vesselin drug balloon. It is understood that the patient is in his 40s. After exercise, he will have chest pain, shortness of breath and other conditions. The symptoms occur repeatedly and need to be hospitalized for surgery. After detailed examination, it was found that there were multiple stenoses in the patient’s coronary vessels, of which two segments were seriously stenosed, and the stenosed vessels needed to be opened through interventional therapy. In the process of communication, patients and their families were more resistant to the traditional treatment methods of metal stent implantation. After full communication and condition analysis, the professional team finally selected the representative innovative products of “intervention without implantation” – bioabsorbable stent and drug balloon for the young patient with coronary heart disease according to the actual situation of blood vessels, and the operation achieved good treatment results.
It is reported that the two “interventional non implantable Innovation Medical Management Co.Ltd(002173) devices used in the above operations were developed by Lepu Medical Technology (Beijing) Co.Ltd(300003) leading enterprise of cardiovascular medical devices in China. Among them, neovas bioabsorbable stent was approved by the State Food and Drug Administration in 2019, which is the first fully degradable stent product approved in China.
bioabsorbable stent: it “disappeared” after implantation for three years, and the blood vessels were intact
It is understood that traditional metal stents can help patients open narrow blood vessels. However, they will remain in the body permanently after implantation. In the long term, there may be safety risks such as thrombosis and in stent restenosis. In addition, some patients may have worry, anxiety and other emotions due to the permanent retention of “metal” in the body. The emergence of fully degradable scaffolds solves the shortcomings of the metal scaffolds mentioned above.
It is understood that Lepu Medical Technology (Beijing) Co.Ltd(300003) of this fully degradable stent neovas bioabsorbable stent, its biggest highlight lies in the matrix of the stent, which selects a fully degradable polymer material – L-polylactic acid (PLLA). After being implanted into the human body, the stent can maintain the supporting force equivalent to that of the metal stent within one year. With the completion of vascular repair, Neovas bioabsorbable scaffolds were completely degraded into water and carbon dioxide in about 3 years, and finally completely discharged from the body, and the blood vessels also recovered their normal elasticity and systolic and diastolic functions. While the stent “disappeared without trace”, the patient has a better long-term prognosis.
It is worth mentioning that neovas bioabsorbable stent is also coated with anti proliferative drug rapamycin, which can effectively prevent the occurrence of vascular restenosis caused by the excessive proliferation of smooth muscle cells in blood vessels. Add another “protective wall” for patients with coronary heart disease to regain a healthy heart.
drug balloon: withdraw from the human body after treatment, no foreign body remains, and the patient regains the “original” natural blood vessel
Vesselin drug balloon is one of the products with the concept of “interventional non implantation”. Compared with the traditional metal stent, its biggest feature is that it has no foreign body implantation and can inhibit the occurrence of vascular restenosis. For example, a drug balloon is like a long magic balloon coated with drugs that can inhibit vascular restenosis. When the dry balloon reaches the position of vascular disease, it will be filled by pressurization and close to the vascular wall to open the narrow vascular cavity. At the same time, the drug coating on the balloon wall will be quickly released to the vascular wall, thus inhibiting the excessive proliferation of vascular endothelium To prevent the subsequent occurrence of intravascular restenosis, it can be used for small blood vessels, bifurcation lesions, opening lesions and so on.
“intervention without implantation” innovative products provide new hope for the treatment of patients with coronary heart disease
With the “fully degradable vascular stent” being written into the outline of the 14th five year plan, more and more doctors and patients began to pay attention to this kind of medical devices and technologies. It is understood that in addition to the neovas bioabsorbable stent and vesselin drug balloon used in the above surgery, the “interventional non implantation” combination of Lepu Medical Technology (Beijing) Co.Ltd(300003) also includes vesscide cutting balloon, which is the only domestic product of the same kind on the market. The advent of the innovative product “intervention without implantation” has provided clinicians and patients with coronary heart disease with more surgical options, bringing new hope for the treatment of patients with coronary heart disease.
